Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
52.94
-0.01 (-0.02%)
At close: Apr 28, 2026, 4:00 PM EDT
52.94
0.00 (0.00%)
Pre-market: Apr 29, 2026, 7:54 AM EDT
Terns Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Terns Pharmaceuticals stock have an average target of 45.22, with a low estimate of 7.44 and a high estimate of 54. The average target predicts a decrease of -14.58% from the current stock price of 52.94.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Terns Pharmaceuticals stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 6 | 6 | 6 | 6 | 4 | 4 |
| Hold | 2 | 1 | 1 | 1 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Apr 27, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $44 → $45 | Buy | Maintains | $44 → $45 | -15.94% | Apr 14, 2026 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $56 → $53 | Strong Buy → Hold | Downgrades | $56 → $53 | +0.11% | Mar 31, 2026 |
| Barclays | Barclays | Buy → Hold Downgrades $56 → $53 | Buy → Hold | Downgrades | $56 → $53 | +0.11% | Mar 30, 2026 |
| Citizens | Citizens | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.19
from -1.03
EPS Next Year
-1.51
from -1.19
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.84 | -1.03 | ||||||
| Avg | -1.19 | -1.51 | ||||||
| Low | -1.45 | -1.78 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.